Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (January 2022)
25 slides from Axim Biotechnologies's investor presentation, January 2022
Slide 1: Company Presentation
Company Presentation OTCQB: AXIM Winter 2022
Slide 2: Safe Harbor
SAFE HARBOR The statements made by Axim Biotechnologies Inc., in this presentation may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-
Slide 3: AXIM – Point of Care Diagnostics
AXIM – POINT OF CARE DIAGNOSTICS Diagnostics Eyes COVID Cancer • AXIM is an international • AXIM is working with two • AXIM’s COVID-19 • AXIM is working on a diagnostic company highly specialized point-of- neutralizing antibody test blood test for the pioneering the discovery care (POC) lab testing
Slide 4: Market Opportunities
MARKET OPPORTUNITIES $249B 6.6% $84B Early Cancer Diagnostic Market Dry Eye Disease Market COVID-19 Diagnostics Market Global cancer diagnostics Global market is expected Global market is estimated market size is expected to to grow at a CAGR of at USD 84.4 billion in 2020 reach $249.6 billion by 20
Slide 5: Diagnostic Assay Pipeline
DIAGNOSTIC ASSAY PIPELINE Submitted PRODUCT INDICATION Pre-clinical Phase 1 Phase 2 Phase 3 FDA Cleared Commercialization to FDA Rapid Diagnostic Lateral Flow Test - Dry Eye Disease (DED) Q1 2022 Lactoferrin Rapid Diagnostic Lateral Flow Test - Dry Eye Disease (DED) Q1 2022 IGE COVID-19 Neutralizing
Slide 6: AXIM Eye
AXIM EYE • 20 million people in the United States (344 million people worldwide) have Dry Eye Disease • Acquired two FDA Approved 510 (k)’s for Diagnostic Testing of Dry Eye Disease • Tests are Non-invasive - Rapid Lateral Flow Assays using tears • The first is a rapid (10-minute) lateral flow diagn
Slide 7: Easy to Use - Point of Care - Quantitative Tests
EASY TO USE - POINT OF CARE - QUANTATITIVE TESTS Using the Tear Deposit tear Add 2 drops of chase Insert the cassette Capture Device, sample in the buffer solution into the reader obtain 0.5µl of tears cassette 10 minutes results will automaticaly appear OTCQB: AXIM 7
Slide 8: Dry Eye Disease Market
DRY EYE DISEASE MARKET FDA Cleared Company Test Type CLIA Level Dry-Eye Tests Osmolarity Tear Lab Non-differential Class I Lactoferrin AXIM Differential Class II Tear IgE AXIM Differential Class II MMP9 Quidel Yes/No Class I Adenovirus Quidel Yes/No Class I The global dry eye syndrome market size wa
Slide 9: Point-of-Care Testing = Financial Opportunity
POINT-OF-CARE TESTING = FINANCIAL OPPORTUNITY LACTOFERRIN IgE Both #PATIENTS NO RETEST 1 RETEST* TESTED 2021 CMS RATES $17.27 $16.46 $33.73 PER DAY PER EYE PRODUCT COST $10.50 $10.50 $21.00 1 $6,110 $9,224 GROSS PROFIT $6.77 $5.96 $12.73 5 $30,550 $46,120 GROSS PROFIT POTENTIAL WITH 5 DAY WEEK AND 1
Slide 10: COVID-19 Testing
COVID-19 TESTING DIVISION INFORMATION COVID PROGRAM • AXIM’s subsidiary Sapphire Biotech is a pioneer in the research and development of diagnostic tools for the early screening of cancer. Our researchers have been able to quickly adapt our existing research and products currently under development
Slide 11: Not All Antibodies Are Created Equal
NOT ALL ANTIBODIES ARE CREATED EQUAL • Only neutralizing antibodies (nAbs) block binding and entry of the SARS-CoV-2 virus into human host cells • However, despite recovering from the disease, not all individuals make high levels of Nabs • Up to 30% do not make measurable levels of NAbs • The goal o
Slide 12: NAb Levels Decline at Different Rates After Vaccination
NAB LEVELS DECLINE AT DIFFERENT RATES AFTER VACCINATION • Monitoring of Vaccine recipients (Pfizer and Moderna combined) after 2nd vaccine dose • Each line is an individual vaccine recipient • % Neutralization on the y-axis was calculated as 1-(Test line Density/LOD)*100%. LOD= 942,481 13 OTCQB: AXI
Slide 13: Lateral Flow POC Test
LATERAL FLOW POC TEST • Drop of whole blood • Rapid: 10 minutes time to result • Portable • Inexpensive compared to laboratory tests • Point-of-Care/At Home Testing/Telemedicine Finger-Stick whole blood • Monitors rise and fall in neutralizing antibodies in response to vaccine or natural infection •
Slide 14: LFA Manufacturing
LFA MANUFACTURING Empowered Diagnostics, Inc. • Pompano Beach, Florida, USA • Facility was the largest lateral flow Signed pregnancy test manufacturer in the world Distribution and • Tech transfer complete Manufacturing • EUA filed for Point-Of-Care with FDA Agreement • Filed CE Mark for Europe • Fi
Slide 15: ImmunoPass
IMMUNOPASS Signed Distribution and Manufacturin g Agreement OTCQB: AXIM 16
Slide 16: Oncology
ONCOLOGY DIVISION INFORMATION ONCOLOGY • Our diagnostic platform is driven by discovery of tumor-derived QSOX1-L biomarker in blood. QSOX1-L biomarker is not present, or present at low levels in healthy individuals. Quantitative tests that detect • QSOX1-L will determine if levels correlate with i)
Slide 17: Oncology Market Size
ONCOLOGY MARKET SIZE 7.4% 10 • The global oncology drugs market • QSOX1-L is over expressed in 10 was valued at $128B in 2019, and cancers including lung, prostate, is projected to reach $222B by breast, brain, kidney, bladder, 2027, registering a CAGR of 7.4% pancreatic • Gives AXIM a pipeline for
Slide 18: QSOX1 Highly Specific for Malignant Cancers
QSOX1 HIGHLY SPECIFIC FOR MALIGNANT CANCERS QSOX1 • We discovered (QSOX1) as a Biomarker in tumor derived proteins • Low cost, non-invasive Rapid Diagnostic Test • QSOX1 is over-expressed in multiple for point-of-care for human cancers, it is not expressed or multiple cancers minimally expressed in
Slide 19: AXIM Manufactures the Biologics Internally
AXIM MANUFACTURES THE BIOLOGICS INTERNALLY • BSL2 LAB IN SAN DIEGO • AXIM foresaw the biologics supply chain problem early-on • China - Expensive • All Biological reagents are proprietary and manufactured in-house • Our ACE2 is 10 times more potent and longer shelf life (patent pending) • Creates ad
Slide 20: Management Team
MANAGEMENT TEAM JOHN W. HUEMOELLER II CHAIRMAN, JEFFERY BUSBY ROBERT MALASEK CHIEF EXECUTIVE OFFICER, PRESIDENT SENIOR VP BUSINESS DEVELOPMENT CHIEF FINANCIAL OFFICER, SECRETARY Mr. Huemoeller has over 30 years’ experience in Mr. Busby brings more than 30 years’ experience Mr. Malasek’s experience i
Slide 21: World Class Science Team
WORLD CLASS SCIENCE TEAM JOSEPH TAUBER, MD SERGEI SVAROVSKY, PHD, MBA DOUGLAS LAKE, PHD Recognized authority in the field of ocular Physical Chemist, with NCI, Pfizer Point-of-Care Associate Professor, ASU and Mayo Clinic. Molecular surface diseases diagnostic projects Philips, Roche, Bio-Rad, and C
Slide 22: Renowned Scientific Medical Advisory Board
RENOWNED SCIENTIFIC MEDICAL ADVISORY BOARD DR. KELLY K. NICHOLS, O.D., M.P.H., Ph. D. DR. HENRY D. PERRY, MD A founding member of the Ocular Surface Society of A recipient of the Life Achievement Award from the American Optometry, Dr. Nichols currently serves as Dean of the Academy of Ophthalmology,
Slide 23: Near & Mid Term Objectives
NEAR & MID TERM OBJECTIVES • Creating new marketing materials, planning launch 1st Q 2022 • Revenue generation through FDA approved DED diagnostics • CLIA Waiver Application • Awaiting FDA approval on EUA • Clinical studies for Gen 2 Antibody Test • Achieving profitability in end of 2022 OTCQB: AXIM
Slide 24: Compelling Opportunity
COMPELLING OPPORTUNITY • AXIM has a world-class science team • We anticipate strong demand for our Covid test that measures neutralizing antibodies • Our Covid test is fast, portable and inexpensive • Able to manufacture 7 million tests a week • Five COVID-19 related patents pending - 4 for cancer,
Slide 25: For Further Information, Please Contact
FOR FURTHER INFORMATION, PLEASE CONTACT: John Huemoeller II – CEO Tel. +1 858-923-4422 info@aximbiotech.com www.aximbiotech.com
Axim Biotechnologies — Investor Presentation (January 2022) on 6ix